{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:14:12Z","timestamp":1781813652068,"version":"3.54.5"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The use of rivaroxaban, an oral direct factor Xa inhibitor, has only been described in a small number of publications in cats. The study objective was to describe the use of rivaroxaban in a large population of hospitalised cats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases were retrospectively identified from June 2017 to July 2024 at seven veterinary specialty hospitals. Any cat prescribed rivaroxaban was eligible for inclusion. Data extracted from the medical records included signalment (age, sex, breed), body weight, reason for commencing rivaroxaban, dose and duration of rivaroxaban, concurrent anticoagulant and antiplatelet therapies, potential rivaroxaban adverse effects, and outcome. Non-parametric descriptive statistics are reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 66 cats were included. Median rivaroxaban dose was 2.5\u202fmg (Min-Max 1.25\u201310, Q1-Q3 2.5\u20135.0), equal to 0.73\u202fmg\/kg\/day (Min-Max 0.28\u20131.87, Q1-Q3 0.53\u20131.0). A total of 36 cats (54.5%) were within the suggested dose range of 0.5\u20131\u202fmg\/kg\/day of the Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines, 14 (21.2%) were below, while 16 (24.2%) were above. Median duration of rivaroxaban was 26.5\u202fdays (Min-Max 0\u2013442, Q1-Q3 2\u201360), although followup was variable. The indication for rivaroxaban administration was confirmed thrombosis (48, 72.7%), strong clinical suspicion of thrombosis (6, 9.1%), and prophylaxis (12, 18.2%). Most thrombi were arterial, including aortic thromboembolism affecting both pelvic limbs (25\/54 cats with thrombosis, 46.3%), arterial thrombosis affecting a single limb (16, 29.6%), and cardiac chamber thrombus (7, 13%). Cardiac disease was the most common thrombosis risk factor (53\/66, 80.3%). Other CURATIVE defined risk factors included immune-mediated haemolytic anaemia in four cats (6.1%) and sepsis in one cat. Other thromboprophylaxis administered included clopidogrel in 58 cats (87.9%), dalteparin in 8 cats (12.1%), and aspirin in 4 cats (6.1%). Potential adverse effects prompting rivaroxaban discontinuation included one case each of vomiting, a cerebrovascular accident, gastrointestinal bleeding, and haemorrhagic pleural effusion. Forty-five cats (68.2%) survived to hospital discharge, 14 (21.2%) were euthanised, two (3%) died, and five (7.6%) were taken home against medical advice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Rivaroxaban was well tolerated in a large population of cats, predominantly prescribed for arterial thrombosis associated with cardiac disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fvets.2025.1561003","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:39:29Z","timestamp":1750433969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Indications and outcomes of rivaroxaban use in cats"],"prefix":"10.3389","volume":"12","author":[{"given":"Ella","family":"Yarsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire R.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrin J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonbum","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/vec.12803","article-title":"Safe and effective anticoagulation in small animals - is that too much to ask? Long-awaited first steps","volume":"29","author":"Chan","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/vec.12801","article-title":"American College of Veterinary Emergency and Critical Care (ACVECC) consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE) guidelines: small animal","volume":"29","author":"Goggs","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/vec.12797","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 1-defining populations at risk","volume":"29","author":"deLaforcade","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/vec.12791","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 2-defining rational therapeutic usage","volume":"29","author":"Goggs","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/vec.12795","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 3-defining antithrombotic protocols","volume":"29","author":"Blais","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/vec.12794","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 4-refining and monitoring antithrombotic therapies","volume":"29","author":"Sharp","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/vec.12796","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 5-discontinuation of anticoagulant therapy in small animals","volume":"29","author":"Brainard","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/vec.13204","article-title":"2022 update of the consensus on the rational use of Antithrombotics and Thrombolytics in veterinary critical care (CURATIVE) domain 1- defining populations at risk","volume":"32","author":"deLaforcade","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/vec.13227","article-title":"Update of the consensus on the rational use of Antithrombotics and Thrombolytics in veterinary critical care (CURATIVE) domain 6: defining rational use of thrombolytics","volume":"32","author":"Sharp","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jvim.15745","article-title":"ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats","volume":"34","author":"Luis Fuentes","year":"2020","journal-title":"J Vet Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/00498250500250493","article-title":"Pharmacokinetics of BAY 59-7939 \u2013 an oral, direct factor Xa inhibitor \u2013 in rats and dogs","volume":"35","author":"Weinz","year":"2005","journal-title":"Xenobiotica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cjca.2022.02.029","article-title":"Canadian cardiovascular society 2022 guidelines for peripheral arterial disease","volume":"38","author":"Primary","year":"2022","journal-title":"Can J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.jtha.2024.02.011","article-title":"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19","volume":"22","author":"Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e27838","DOI":"10.7759\/cureus.27838","article-title":"Comparison of the efficacy and safety of Apixaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: a Meta-analysis","volume":"14","author":"Memon","year":"2022","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct Oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/vec.12524","article-title":"Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats","volume":"26","author":"Dixon-Jimenez","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1098612X211013736","article-title":"Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease","volume":"24","author":"Lo","year":"2022","journal-title":"J Feline Med Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jvc.2024.01.002","article-title":"Arterial thromboembolism in a cat with transient myocardial thickening","volume":"52","author":"Vollmar","year":"2024","journal-title":"J Vet Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.14202\/vetworld.2024.796-803","article-title":"Rivaroxaban versus enoxaparin plus clopidogrel therapy for hypertrophic cardiomyopathy-associated thromboembolism in cats","volume":"17","author":"Jaturanratsamee","year":"2024","journal-title":"Vet World"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.24.09.0584","article-title":"Therapy with clopidogrel or rivaroxaban has equivalent impacts on recurrence of thromboembolism and survival in cats following cardiogenic thromboembolism: the SUPERCAT study","volume":"263","author":"Brainard","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1098612X241257878","article-title":"Feline aortic thromboembolism: recent advances and future prospects","volume":"26","author":"Guillaumin","year":"2024","journal-title":"J Feline Med Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1939-1676.2008.0048.x","article-title":"Portal vein thrombosis in cats: 6 cases (2001-2006)","volume":"22","author":"Rogers","year":"2008","journal-title":"J Vet Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/jsap.13470","article-title":"Computed tomographic features of portal vein thrombosis in two cats with splenosystemic shunts","volume":"63","author":"Sakamoto","year":"2022","journal-title":"J Small Anim Pract"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2460\/javma.1999.215.11.1650","article-title":"Pulmonary thromboembolism in cats: 29 cases (1987-1997)","volume":"215","author":"Norris","year":"1999","journal-title":"J Am Vet Med Assoc"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1939-1676.2004.tb02580.x","article-title":"Pulmonary thromboembolism in cats","volume":"18","author":"Schermerhorn","year":"2004","journal-title":"J Vet Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.jvc.2015.10.004","article-title":"Secondary prevention of cardiogenic arterial thromboembolism in the CAT: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)","volume":"17","author":"Hogan","year":"2015","journal-title":"J Vet Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1137774","DOI":"10.3389\/fvets.2023.1137774","article-title":"The standards of reporting randomized trials in pets (PetSORT): methods and development processes","volume":"10","author":"Ruple","year":"2023","journal-title":"Front Vet Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1137781","DOI":"10.3389\/fvets.2023.1137781","article-title":"The standards of reporting trials in pets (PetSORT): explanation and elaboration","volume":"10","author":"Sargeant","year":"2023","journal-title":"Front Vet Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/jvim.16727","article-title":"Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats","volume":"37","author":"Lo","year":"2023","journal-title":"J Vet Intern Med"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1561003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:39:30Z","timestamp":1750433970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1561003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":37,"alternative-id":["10.3389\/fvets.2025.1561003"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2025.1561003","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1561003"}}